You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
In two studies at ESMO, researchers demonstrated the ability of combined biomarker approaches to predict the efficacy of immune checkpoint inhibitors.
Phase I data at ESMO suggested that the experimental drug may be particularly effective in KRAS G12C-mutated lung and colon cancers.
The findings suggested that genomic surveillance of Barrett's esophagus could identify patients who will progress years in advance and enable earlier treatment.
Researchers used the methylCIBERSORT algorithm to determine the makeup of the tumor immune microenvironment of about 6,000 pediatric central nervous system tumors.
The company is employing Guardant360 in a Phase III trial assessing the efficacy of the drug both in a larger population and in women who test positive for ESR1 mutations.
The collaboration seeks to develop RNA-based signatures that could help oncologists predict disease progression and guide the use of precision therapies.
The researchers said their new study supports the clinical utility of their test, which combines genomic and drug screening analyses of organoids to guide cancer treatment.
Researchers concluded that there has been significant expansion of coverage for ctDNA assays over the past four years, but policies remain very heterogeneous and often limited.
A Myriad Genetics-funded team found that an 86-SNV polygenic score could modify breast cancer risk in women with pathogenic mutations in cancer risk genes.
Developers are improving and expanding the software that has been helping match patients to molecularly targeted drugs at the institute for over three years.